WallStSmart

SIGA Technologies Inc (SIGA)vsUnited Therapeutics Corporation (UTHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

United Therapeutics Corporation generates 3265% more annual revenue ($3.18B vs $94.58M). UTHR leads profitability with a 41.9% profit margin vs 24.6%. UTHR appears more attractively valued with a PEG of 2.18. UTHR earns a higher WallStSmart Score of 67/100 (B-).

SIGA

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 5.5Value: 7.3Quality: 8.5
Piotroski: 2/9Altman Z: 6.12

UTHR

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 9.0Value: 10.0Quality: 7.8
Piotroski: 5/9Altman Z: 7.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SIGAUndervalued (+55.7%)

Margin of Safety

+55.7%

Fair Value

$14.98

Current Price

$5.00

$9.98 discount

UndervaluedFair: $14.98Overvalued
UTHRUndervalued (+62.9%)

Margin of Safety

+62.9%

Fair Value

$1282.02

Current Price

$541.60

$740.42 discount

UndervaluedFair: $1282.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SIGA5 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
6.1210/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
24.6%9/10

Keeps 25 of every $100 in revenue as profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

UTHR4 strengths · Avg: 9.5/10
Profit MarginProfitability
41.9%10/10

Keeps 42 of every $100 in revenue as profit

Operating MarginProfitability
45.0%10/10

Strong operational efficiency at 45.0%

Altman Z-ScoreHealth
7.3010/10

Safe zone — low bankruptcy risk

EPS GrowthGrowth
24.5%8/10

Earnings expanding 24.5% YoY

Areas to Watch

SIGA4 concerns · Avg: 2.5/10
Market CapQuality
$357.51M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
3.372/10

Expensive relative to growth rate

Revenue GrowthGrowth
-95.3%2/10

Revenue declined 95.3%

UTHR1 concerns · Avg: 4.0/10
PEG RatioValuation
2.184/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : SIGA

The strongest argument for SIGA centers on Debt/Equity, Altman Z-Score, Profit Margin. Profitability is solid with margins at 24.6% and operating margin at -2.5%.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.

Bear Case : SIGA

The primary concerns for SIGA are Market Cap, Piotroski F-Score, PEG Ratio.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio.

Key Dynamics to Monitor

SIGA profiles as a declining stock while UTHR is a mature play — different risk/reward profiles.

SIGA carries more volatility with a beta of 0.99 — expect wider price swings.

UTHR is growing revenue faster at 7.4% — sustainability is the question.

UTHR generates stronger free cash flow (173M), providing more financial flexibility.

Bottom Line

UTHR scores higher overall (67/100 vs 54/100), backed by strong 41.9% margins. SIGA offers better value entry with a 55.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

SIGA Technologies Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health safety and infectious disease markets in the United States. The company is headquartered in New York, New York.

Visit Website →

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?